#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Emphysema Congenital megacolon Acquired haemophilia Angiosarcoma recurrent Hypergammaglobulinaemia benign monoclonal Narcolepsy Human papilloma virus immunisation Immune-mediated enterocolitis Dedifferentiated liposarcoma Transitional cell cancer of the renal pelvis and ureter Ovarian cancer B-cell small lymphocytic lymphoma refractory Cutaneous T-cell lymphoma recurrent Cystic fibrosis Fibrosarcoma More trials…

    Learn about Rare Diseases

    Mucous membrane pemphigoid – Trials in Disease Progressive multifocal leukoencephalopathy – Life with Disease Factor IX deficiency Glycogen storage disease type V – Treatment Vascular malformation – Basic Information Wolfram syndrome Encephalitis autoimmune – Life with Disease Skin angiosarcoma Krabbe’s disease – Trials in Disease Antithrombin III deficiency – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Chloride Ion Avacincaptad Pegol Sumatriptan Succinate Zilucoplan Sodium Trehalose Dihydrate (Ph.eur.) Dapirolizumab Pegol Lovastatin ZIGAKIBART Delandistrogene Moxeparvovec Trametinib Dimethyl Sulfoxide His203-Crm197 Zibotentan Polatuzumab Vedotin Sym025 Bjt-778 Iptacopan Hydrochloride Rosnilimab Ion440 Nms-03592088 Jnj-81241459 More therapies…

    Learn about Your Condition

    Carotid arteriosclerosis Eye disorder Metastatic gastric cancer Muscle strain Cutaneous lupus erythematosus Lumbosacral radiculopathy Leiomyosarcoma recurrent Vulval cancer recurrent Apheresis Pleomorphic leiomyosarcoma Metachromatic leukodystrophy Anaemia Colon cancer stage IV Rectal cancer recurrent Myocardial ischaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Hippokrateslaan 10, Batiment 54, Woluwe-Saint-Lambert, 1200, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Nirogacestat in adult premenopausal women with desmoid tumors and aggressive fibromatosis to evaluate ovarian function recovery

    Recruiting

    3 1 1
    Investigated Diseases:
    • Desmoid tumour
    Investigated Drugs:
    • Nirogacestat Hydrobromide
    Belgium Germany Italy The Netherlands Spain

  • Study of risankizumab safety and effectiveness in children and teenagers aged 2-17 years with moderate to severe ulcerative colitis

    Recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Belgium Germany Greece Italy Poland Spain +1

  • Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

    Recruiting

    3 1
    Investigated Diseases:
    • Vitiligo
    Investigated Drugs:
    • Ruxolitinib
    Austria Belgium Bulgaria Denmark France Germany +6

  • Long-term safety study of subcutaneous vedolizumab in children and adolescents with ulcerative colitis or Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Investigated Drugs:
    • Vedolizumab
    Belgium Bulgaria Denmark Ireland Italy The Netherlands +4

  • Study of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis

    Recruiting

    3 1
    Investigated Drugs:
    • Deucravacitinib
    Belgium Germany Hungary Italy Poland Romania +1

  • Study of Nucresiran in Adults with Transthyretin Amyloidosis with Cardiomyopathy to Evaluate its Effects on Survival and Heart Problems

    Recruiting

    3 1
    Investigated Diseases:
    • Cardiomyopathy
    Austria Belgium Czechia Denmark France Germany +12

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Leuprorelin Acetate
    • Anastrozole
    Belgium France Greece Ireland Italy Poland +1

  • Study of felzartamab compared to placebo in adults with IgA nephropathy

    Recruiting

    3 1 1
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Codeine Phosphate
    • Desloratadine
    Belgium Bulgaria Croatia Czechia France Germany +5

  • Study of MK-2214 to slow disease progression in people with early Alzheimer’s disease

    Recruiting

    2 1
    Investigated Drugs:
    • Florquinitau (18F)
    Belgium The Netherlands Spain

  • Study of Zolbetuximab combined with Paclitaxel and Ramucirumab for patients with previously treated CLDN18.

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Zolbetuximab
    Belgium
Previous Page
1 … 7 8 9 10 11 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!